Precision therapies take aim at non-Hodgkin’s lymphoma

Elie Dolgin

Nature, 2018, vol. 563, issue 7731, S46-S47

Abstract: The dramatic success of ibrutinib has created a more hopeful reality for people with lymphoma, as targeted therapies fill the pipeline.

Keywords: Cancer; Drug discovery; Therapeutics; Cell biology (search for similar items in EconPapers)
Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-018-07363-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:563:y:2018:i:7731:d:10.1038_d41586-018-07363-4

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-018-07363-4

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().